Angelman Syndrome - Pipeline Insight, 2020

Publisher Name :
Date: 24-Sep-2020
No. of pages: 75
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Angelman Syndrome - Pipeline Insight, 2020," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Angelman Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Angelman Syndrome Understanding

Angelman Syndrome: Overview

Angelman syndrome is a rare genetic and neurological disorder characterized by severe developmental delay and learning disabilities; absence or near absence of speech; inability to coordinate voluntary movements (ataxia); tremulousness with jerky movements of the arms and legs and a distinct behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling. Although those with the syndrome may be unable to speak, many gradually learn to communicate through other means such as gesturing. In addition, children may have enough receptive language ability to understand simple forms of language communication.

Symptoms

Children with Angelman syndrome experience delays in reaching developmental milestones (developmental delays) and have severe learning disabilities. Children with Angelman syndrome also have significant communication difficulties. Most children do not develop the ability to speak more than a few words. Children usually can understand simple commands. Older children and adults may be able to communicate through gesturing and or using communication boards.

Diagnosis

A diagnosis of Angelman syndrome may be made based upon a detailed patient history, a thorough clinical evaluation and identification of characteristic findings. About 80% of cases can be confirmed through a variety of specialized blood tests such as DNA methylation (detects, but does not discriminate between chromosome deletion, imprinting center defect and paternal uniparental disomy).

Fluorescent in situ hybridization (FISH) or, most commonly, microarray chromosome analysis can detect the characteristic deletion (seen in 70% of cases) of chromosome 15q11-q13 in cells of the body.

Treatment

At this time, therapies for Angelman syndrome are symptomatic and supportive. Anti-seizure medications (anticonvulsants) are helpful to those experiencing seizures. Ankle braces/supports and physical therapy can help in achievement of walking. Scoliosis can develop in about 10% and may require braces or surgical correction.

Angelman Syndrome Emerging Drugs Chapters

This segment of the Angelman Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Angelman Syndrome Emerging Drugs

- GTX-102: GeneTx Biotherapeutics / Ultragenyx Pharmaceutical Inc.

GTX-102 is an investigational antisense oligonucleotide designed to target and inhibit expression of UBE3A-AS. Nonclinical studies show that GTX-102 reduces the levels of UBE3A-AS and reactivates expression of the paternal UBE3A allele in neurons of the CNS. Reactivation of paternal UBE3A expression in animal models of Angelman syndrome has been associated with improvements in some of the neurological symptoms associated with the condition.

The Phase 1/2 KIK-AS (Knockdown of UBE3A-antisense in Kids with Angelman Syndrome) study is an ongoing open-label, multiple-dose, dose-escalating study will enroll 20 patients to evaluate the safety, tolerability, and potential efficacy of GTX-102 in pediatric patients with Angelman syndrome. Preliminary data from the first cohorts of the study are expected in the first half of 2021.

Further product details are provided in the report……..

Angelman Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Angelman Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Angelman Syndrome

There are approx. 5+ key companies which are developing the therapies for Angelman Syndrome. The companies which have their Angelman Syndrome drug candidates in the mid to advanced stage, i.e. phase III and Phase I/II include, Ovid Therapeutics Inc., GeneTX Biotherapeutics, LLC etc.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

- Mid-stage products (Phase II and Phase I/II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Angelman Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Intrathecal

- Molecule Type

Products have been categorized under various Molecule types such as

- Small molecules

- Gene therapies

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Angelman Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angelman Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angelman Syndrome drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Angelman Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Angelman Syndrome.

- GTX-102 has been granted Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). In August 2019, GeneTx and Ultragenyx announced a partnership to develop GTX-102, with Ultragenyx receiving an exclusive option to acquire GeneTx.

Angelman Syndrome Report Insights

- Angelman Syndrome Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Angelman Syndrome Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Angelman Syndrome drugs?

- How many Angelman Syndrome drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angelman Syndrome?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Angelman Syndrome therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Angelman Syndrome and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- GeneTX Biotherapeutics, LLC

- Ultragenyx Pharmaceutical Inc

- Hoffmann-La Roche

- Ovid Therapeutics Inc.

- Biogen

Key Products

- GTX-102

- RO7248824

- OV101

Angelman Syndrome - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
Angelman Syndrome: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Angelman Syndrome - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
* Angelman Syndrome companies' collaborations, Licensing, Acquisition -Deal Value Trends
Angelman Syndrome Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
* Comparative Analysis
OV101: Ovid Therapeutics Inc.
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase I/II)
* Comparative Analysis
GTX-102: GeneTX Biotherapeutics, LLC
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
* Comparative Analysis
RO7248824: Roche
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
* Comparative Analysis
Research programme: Cognitive Disorder Gene Therapy: PTC Therapeutics
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
Angelman Syndrome Key Companies
Angelman Syndrome Key Products
Angelman Syndrome- Unmet Needs
Angelman Syndrome- Market Drivers and Barriers
Angelman Syndrome- Future Perspectives and Conclusion
Angelman Syndrome Analyst Views
Angelman Syndrome Key Companies
Appendix

List of Tables

Table 1 Total Products for Angelman Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Angelman Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global High Pure PCR Product Market Growth 2020-2025
    Published: 22-Oct-2020        Price: US 3660 Onwards        Pages: 132
    According to this study, over the next five years the High Pure PCR Product market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in High Pure PCR Product business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of High Pure PCR Product market ......
  • Global Anti-Anxiety Drugs Market Growth 2020-2025
    Published: 22-Oct-2020        Price: US 3660 Onwards        Pages: 137
    According to this study, over the next five years the Anti-Anxiety Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Anti-Anxiety Drugs business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Anxiety Drugs market by produc......
  • Global Felodipine Sustained-Release Tablet Market Growth 2020-2025
    Published: 22-Oct-2020        Price: US 3660 Onwards        Pages: 139
    According to this study, over the next five years the Felodipine Sustained-Release Tablet market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Felodipine Sustained-Release Tablet business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of F......
  • Global Paroxetine Hydrochloride Tablet Market Growth 2020-2025
    Published: 22-Oct-2020        Price: US 3660 Onwards        Pages: 136
    According to this study, over the next five years the Paroxetine Hydrochloride Tablet market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Paroxetine Hydrochloride Tablet business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Paroxetin......
  • Global Escitalopram Oxalate Market Growth 2020-2025
    Published: 22-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Escitalopram Oxalate market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Escitalopram Oxalate business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Escitalopram Oxalate market by ......
  • Global Sertraline Hydrochloride Tablet Market Growth 2020-2025
    Published: 22-Oct-2020        Price: US 3660 Onwards        Pages: 161
    According to this study, over the next five years the Sertraline Hydrochloride Tablet market will register a XX%% CAGR in terms of revenue, the global market size will reach $ XX million by 2025, from $ XX million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Sertraline Hydrochloride Tablet business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Sertralin......
  • 2020-2029 Report on Global Hydroxyzine Pamoate Oral Capsule Market by Player, Region, Type, Application and Sales Channel
    Published: 22-Oct-2020        Price: US 2500 Onwards        Pages: 106
    The global Hydroxyzine Pamoate Oral Capsule market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2020 and 2029. Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 210 countries and territories around the world and 2 international conveyances. The global impacts of COVID-19 are already starting to be felt, and will significantly aff......
  • (Post-pandemic Era) - Global Plasma Protein Therapeutics Market Assessment, With Major Companies Analysis, Regional Analysis, Breakdown Data by Application/Type
    Published: 21-Oct-2020        Price: US 4860 Onwards        Pages: 82
    Summary This study analysis was given on a worldwide scale, for instance, present and historical Plasma Protein Therapeutics growth analysis, competitive analysis, and also the growth prospects of the major regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from production, revenue and consumption. A quantitative and qualitative analysis of the main players ......
  • (Post-pandemic Era) - Global Plasma Protein Therapeutics Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
    Published: 21-Oct-2020        Price: US 3650 Onwards        Pages: 108
    Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly opt......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs